Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Exelixis
University of Pittsburgh
Yale University
University of Kentucky
AHS Cancer Control Alberta
Biogen
Medical College of Wisconsin
Australian & New Zealand Children's Haematology/Oncology Group
Alliance for Clinical Trials in Oncology
University Medical Center Groningen
University of Virginia
Hoosier Cancer Research Network
Instituto Nacional de Cancerologia de Mexico
Technische Universität Dresden
OHSU Knight Cancer Institute
Hoffmann-La Roche
AC Camargo Cancer Center
Pfizer
Duke University
Alliance for Clinical Trials in Oncology
Karyopharm Therapeutics Inc
Rush University Medical Center
OHSU Knight Cancer Institute
Wake Forest University Health Sciences
University of Colorado, Denver
Indiana University
Duke University
National Institutes of Health Clinical Center (CC)
Children's Hospital Medical Center, Cincinnati
Canadian Cancer Trials Group
Centre Leon Berard
University of Michigan Rogel Cancer Center
University of Pittsburgh
University Hospital Tuebingen
Daiichi Sankyo
Medical College of Wisconsin
Children's Hospital of Philadelphia
St. Olavs Hospital
Maastricht Radiation Oncology
Duke University
British Columbia Cancer Agency
Angiochem Inc
Dr. Negrin University Hospital
GlaxoSmithKline
Case Comprehensive Cancer Center
Arog Pharmaceuticals, Inc.
AIO-Studien-gGmbH
University of Cincinnati
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)